See more : Hatsun Agro Prod Ltd-RE (HATSUN-RE.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Absci Corporation (ABSI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Absci Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Metals Australia Ltd (MLS.AX) Income Statement Analysis – Financial Results
- Nautilus, Inc. (NLS) Income Statement Analysis – Financial Results
- Flagship Investments Limited (FSI.AX) Income Statement Analysis – Financial Results
- DMG Blockchain Solutions Inc. (DMGGF) Income Statement Analysis – Financial Results
- SW Investments Limited (SW1.BO) Income Statement Analysis – Financial Results
Absci Corporation (ABSI)
About Absci Corporation
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 5.72M | 5.75M | 4.78M | 4.78M | 2.06M |
| Cost of Revenue | 47.57M | 13.04M | 6.65M | 11.45M | 4.31M |
| Gross Profit | -41.85M | -7.29M | -1.87M | -6.67M | -2.25M |
| Gross Profit Ratio | -731.88% | -126.85% | -39.15% | -139.50% | -109.27% |
| Research & Development | 48.07M | 58.91M | 44.59M | 11.45M | 4.31M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 37.83M | 40.55M | 28.78M | 5.50M | 3.52M |
| Other Expenses | 35.33M | 13.04M | 6.65M | 1.13M | 491.00K |
| Operating Expenses | 121.23M | 112.50M | 80.02M | 18.08M | 8.33M |
| Cost & Expenses | 121.23M | 112.50M | 80.02M | 18.08M | 8.33M |
| Interest Income | 0.00 | 972.00K | 3.43M | 634.00K | 268.00K |
| Interest Expense | 1.01M | 972.00K | 3.43M | 634.00K | 268.00K |
| Depreciation & Amortization | 14.00M | 13.04M | 6.65M | 1.13M | 491.00K |
| EBITDA | -95.46M | -91.36M | -99.77M | -12.59M | -5.83M |
| EBITDA Ratio | -1,669.41% | -1,589.63% | -2,086.43% | -263.35% | -282.77% |
| Operating Income | -115.52M | -106.75M | -75.24M | -13.30M | -6.27M |
| Operating Income Ratio | -2,020.20% | -1,857.49% | -1,573.36% | -278.26% | -304.13% |
| Total Other Income/Expenses | 5.05M | 1.39M | -34.62M | -1.05M | -319.00K |
| Income Before Tax | -110.47M | -105.37M | -109.86M | -14.35M | -6.58M |
| Income Before Tax Ratio | -1,931.90% | -1,833.39% | -2,297.34% | -300.27% | -319.61% |
| Income Tax Expense | 100.00K | -461.00K | -8.90M | 216.00K | 217.00K |
| Net Income | -110.57M | -104.90M | -100.96M | -14.57M | -6.80M |
| Net Income Ratio | -1,933.65% | -1,825.37% | -2,111.25% | -304.79% | -330.15% |
| EPS | -1.20 | -1.15 | -1.09 | -0.16 | -0.07 |
| EPS Diluted | -1.20 | -1.15 | -1.09 | -0.16 | -0.07 |
| Weighted Avg Shares Out | 92.03M | 90.85M | 92.65M | 92.25M | 92.25M |
| Weighted Avg Shares Out (Dil) | 92.03M | 90.85M | 92.65M | 92.25M | 92.25M |
Absci Corporation (ABSI) Q3 2024 Earnings Call Transcript
Absci Corporation (NASDAQ:ABSI ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and Chief Business Officer Christian Stegmann...
Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates
Absci Corporation (ABSI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago.
Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration
Absci to Host R&D Day on December 12, 2024
VANCOUVER, Wash. and NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will host its 2024 R&D Day on Thursday, December 12th in New York City.
Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024
VANCOUVER, Wash. and NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the third quarter before...
Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile
Absci Corporation's initiation of a phase 1 study using ABS-101 for the treatment of patients with IBD expected early 2025, with interim data to be released in the 2nd half of 2025. ABS-101 aims to differentiate itself with unique features...
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood bought shares of Tempus AI, Blade Air Mobility, and Absci on Thursday. Tempus AI was a broken IPO shortly after going public two months ago, but it soared 34% in August.
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.
Absci Corporation (ABSI) Q2 2024 Earnings Call Transcript
Absci Corporation (NASDAQ:ABSI ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and CEO Zach Jonasson - CFO and Chief Business Officer Christian Stegmann...
Absci Corporation (ABSI) Reports Q2 Loss, Lags Revenue Estimates
Absci Corporation (ABSI) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.27 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports